Showing results (1981-1990 of 2,044) with videos related to

Sort By:
Pageof 205
The Lancet. Neurology|May 17, 2024
Climate change and disorders of the nervous systemSanjay M Sisodiya, Medine I Gulcebi, Francesco Fortunato, et al.
Journal of Affective Disorders|February 19, 2026
Genetic predisposition to inflammation and psychopathology: A transdiagnostic network analysisPaula Usemann, Friederike S David, Katharina Brosch, et al.
Bioorganic & Medicinal Chemistry Letters|October 20, 2009
5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinaseJames E Tarver, Theodore C Jessop, Marianne Carlsen, et al.
The Lancet Regional Health. Europe|February 16, 2024
The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysisElla Burchill, Cameron James Watson, Jack B Fanshawe, et al.
Frontiers in Immunology|March 17, 2023
Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospitalFelix Eduardo R Punzalan, Jaime Alfonso M Aherrera, Sheriah Laine M de Paz-Silava, et al.
The Science of the Total Environment|June 2, 2024
The ADnet Bayesian belief network for alder decline: Integrating empirical data and expert knowledgeInês Gomes Marques, Cristina Vieites-Blanco, Patricia M Rodríguez-González, et al.
ACS Omega|March 30, 2026
Structural and Functional Analyses of <i>Trypanosoma brucei</i> Nucleoside Diphosphate KinasePatricia Makori, Michael P Boeckman, Heidi S David, et al.
Translational Psychiatry|June 3, 2024
Factor analysis of lifetime psychopathology and its brain morphometric and genetic correlates in a transdiagnostic sampleAxel Krug, Frederike Stein, Friederike S David, et al.
Molecular Psychiatry|October 20, 2020
Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosisThomas A Pollak, Matthew J Kempton, Conrad Iyegbe, et al.
Journal of Medicinal Chemistry|October 17, 2009
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucomaBryce A Harrison, N Andrew Whitlock, Michael V Voronkov, et al.
Pageof 205